NAD⁺ nasal spray: the delivery format with the least direct evidence

“NAD⁺ nasal spray” is one of the newer entries in the NAD⁺ marketplace: a bottle you spritz into each nostril, sold on the premise that intranasal delivery is a faster, needle-free way to “boost NAD⁺.” The pitch borrows all the excitement built up around NAD⁺ biology and staples it to a convenient format. The problem is that convenience and evidence are two different things — and of the delivery routes people actually buy, the nasal one has by far the least direct human data behind it.

What it actually is

A NAD⁺ nasal spray is a liquid containing either NAD⁺ itself or an NAD⁺ precursor, formulated for intranasal administration. The marketing logic runs in two directions at once: that spraying it into the nose lets NAD⁺ enter the bloodstream while bypassing the gut, and — more ambitiously — that the nasal passage offers a direct “nose-to-brain” shortcut that could raise NAD⁺ in the central nervous system. Both are delivery-format claims. Neither is a claim about NAD⁺ biology, which is a separate and much better-studied question covered in our review of NAD⁺ precursors (NR and NMN).

The delivery question: does spraying it actually do anything?

This is where the format falls down. NAD⁺ is a large, charged, water-soluble molecule — exactly the kind of compound that does not cross mucosal membranes easily. For intranasal delivery to work, a specific formulation has to be engineered and then validated to show it reaches the target, and that validation is highly molecule- and formulation-dependent rather than automatic.^[4] The honest state of the evidence for the NAD⁺ spray specifically: there is essentially no controlled human trial showing that intranasal NAD⁺ raises systemic NAD⁺, let alone brain NAD⁺, in people. The theoretical nose-to-brain route is genuinely interesting, but for this molecule it is unproven — an idea, not a result.

What we do know: the oral precursors

The contrast with oral precursors is stark, and it is the reason this article exists. A controlled human study established that oral nicotinamide riboside (NR) is bioavailable and raises the blood NAD⁺ metabolome in a dose-dependent way — the precursor is absorbed and converted to NAD⁺ as the biochemistry predicts.^[1] A separate randomized, placebo-controlled trial in healthy middle-aged and older adults found chronic NR was well-tolerated and effectively elevated NAD⁺ in blood.^[2] And NMN's most-cited trial randomized prediabetic, postmenopausal women and reported improved skeletal-muscle insulin sensitivity — a small, surrogate-endpoint result, but a real one.^[3]

Read that carefully: the oral data establish that the compound gets in and that the biomarker moves. That is precisely the step the nasal format has never demonstrated. When a spray borrows the credibility of the NAD⁺ story, it is borrowing evidence that belongs to a different delivery route.

How the formats stack up

Among the routes people actually buy, there is a rough hierarchy of directness of evidence. Oral NR/NMN has the most human data for raising measured NAD⁺. NAD⁺ IV therapy delivers the molecule straight into the bloodstream, so systemic exposure is not in doubt, though controlled outcome data remain thin. Subcutaneous NAD⁺ injections occupy a middle ground with even less formal study. The nasal spray sits at the bottom of that list for direct evidence: it is the one format where even the basic “does it reach the bloodstream in humans” question lacks a controlled answer. If you want to compare routes side by side, our NAD⁺ format comparator lays out the trade-offs, and the cost of NAD⁺ therapy varies widely by format too.

The honest bottom line

A NAD⁺ nasal spray is a convenient, needle-free, heavily marketed format riding on genuine excitement about NAD⁺ biology — but it carries the least direct evidence of the common delivery routes. What is supported by human data is narrow and specific: oral precursors are absorbed and raise the NAD⁺ biomarker. What is not supported is that spraying NAD⁺ into your nose raises systemic or brain NAD⁺ at all, and — as with every NAD⁺ format — no route has been shown to slow aging, prevent disease, or deliver a clinical benefit in people. If you are drawn to the spray for convenience, buy it knowing you are paying for a format whose core delivery claim has not been tested, not for a proven result.